To evaluate the strategy of using pathological response-guided non-cross-resistant adjuvant chemotherapy for HR + /HER2-/LN+ breast cancer patients who were non-responsive to NCT, we started this trial in 2010. This evidence concerns the gene HR and breast cancer.